10:14 EDT Gilead (GILD) down 2% to $111.14 after FDA placed hold on some HIV trials
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating
- Gilead Sciences’ Oncology Advancements: Trodelvy’s Potential to Boost Stock Value
- Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating
- Gilead Sciences: Buy Rating Driven by Promising HIV Treatment Pipeline and Strategic Growth Prospects
- Gilead Sciences: Buy Rating Affirmed on Promising Oncology Pipeline and Trodelvy’s Potential as New Standard of Care